GNB3
Basic information
Region (hg38): 12:6839954-6847393
Links
Phenotypes
GenCC
Source:
- congenital stationary night blindness (Supportive), mode of inheritance: AD
- congenital stationary night blindness 1H (Limited), mode of inheritance: AR
- congenital stationary night blindness 1H (Strong), mode of inheritance: AR
- congenital stationary night blindness 1H (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Night blindness, congenital stationary, type 1H | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Ophthalmologic | 27063057 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GNB3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 52 | 62 | ||||
missense | 132 | 135 | ||||
nonsense | 6 | |||||
start loss | 1 | |||||
frameshift | 7 | |||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 4 | 9 | 13 | |||
non coding | 67 | 20 | 87 | |||
Total | 0 | 0 | 155 | 120 | 30 |
Variants in GNB3
This is a list of pathogenic ClinVar variants found in the GNB3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-6841239-G-A | Benign (May 12, 2021) | |||
12-6841289-T-C | Uncertain significance (Dec 02, 2022) | |||
12-6841291-G-A | Uncertain significance (Apr 10, 2023) | |||
12-6841292-G-A | Uncertain significance (May 24, 2023) | |||
12-6841295-A-G | Uncertain significance (May 06, 2021) | |||
12-6841298-T-C | Uncertain significance (Dec 18, 2023) | |||
12-6841309-C-T | Uncertain significance (Nov 20, 2023) | |||
12-6841310-G-A | Uncertain significance (Jan 06, 2024) | |||
12-6841315-G-A | Uncertain significance (Mar 17, 2020) | |||
12-6841319-C-T | Inborn genetic diseases | Uncertain significance (Jan 09, 2024) | ||
12-6841320-G-A | Likely benign (Aug 02, 2021) | |||
12-6841320-G-T | Likely benign (Nov 24, 2022) | |||
12-6841323-G-C | Uncertain significance (Jun 13, 2022) | |||
12-6841326-G-A | Likely benign (Jul 17, 2023) | |||
12-6841328-T-G | Uncertain significance (Jul 30, 2022) | |||
12-6841332-G-A | Likely benign (Oct 03, 2023) | |||
12-6841343-C-T | Uncertain significance (Aug 15, 2022) | |||
12-6841350-T-C | Uncertain significance (Aug 22, 2022) | |||
12-6841358-C-T | Likely benign (Mar 08, 2023) | |||
12-6841363-C-T | Likely benign (May 25, 2022) | |||
12-6841559-CTCCCCTGATGTCTGCTTTCCCTGCAGGA-C | Uncertain significance (Sep 07, 2022) | |||
12-6841567-A-G | Likely benign (Nov 13, 2023) | |||
12-6841577-T-C | Likely benign (Jan 08, 2024) | |||
12-6841601-T-C | Uncertain significance (Jun 05, 2023) | |||
12-6841608-A-G | Uncertain significance (Aug 19, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GNB3 | protein_coding | protein_coding | ENST00000229264 | 9 | 7440 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.33e-11 | 0.0882 | 125692 | 0 | 56 | 125748 | 0.000223 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.05 | 175 | 219 | 0.801 | 0.0000137 | 2230 |
Missense in Polyphen | 56 | 75.972 | 0.73711 | 773 | ||
Synonymous | -0.0823 | 88 | 87.0 | 1.01 | 0.00000602 | 664 |
Loss of Function | 0.322 | 17 | 18.5 | 0.919 | 9.72e-7 | 191 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000724 | 0.000721 |
Ashkenazi Jewish | 0.000103 | 0.0000992 |
East Asian | 0.000111 | 0.000109 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000170 | 0.000167 |
Middle Eastern | 0.000111 | 0.000109 |
South Asian | 0.000438 | 0.000425 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein- effector interaction.;
- Disease
- DISEASE: Night blindness, congenital stationary, 1H (CSNB1H) [MIM:617024]: A form of congenital stationary night blindness, a non-progressive retinal disorder characterized by impaired night vision or in dim light, with good vision only on bright days. CSNB1H patients present with childhood-onset night blindness and middle age-onset photophobia, but have near-normal vision and do not exhibit nystagmus or high myopia. CSNB1H inheritance is autosomal recessive. {ECO:0000269|PubMed:27063057}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- PI3K-Akt signaling pathway - Homo sapiens (human);Relaxin signaling pathway - Homo sapiens (human);Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human);Retrograde endocannabinoid signaling - Homo sapiens (human);GABAergic synapse - Homo sapiens (human);Serotonergic synapse - Homo sapiens (human);Dopaminergic synapse - Homo sapiens (human);Glutamatergic synapse - Homo sapiens (human);Chemokine signaling pathway - Homo sapiens (human);Circadian entrainment - Homo sapiens (human);Apelin signaling pathway - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Cholinergic synapse - Homo sapiens (human);Taste transduction - Homo sapiens (human);Morphine addiction - Homo sapiens (human);Alcoholism - Homo sapiens (human);Platelet Aggregation Inhibitor Pathway, Pharmacodynamics;Beta-agonist/Beta-blocker Pathway, Pharmacodynamics;Corticotropin-releasing hormone signaling pathway;Myometrial Relaxation and Contraction Pathways;G Protein Signaling Pathways;Chemokine signaling pathway;Focal Adhesion-PI3K-Akt-mTOR-signaling pathway;PI3K-Akt Signaling Pathway;Ras Signaling;Calcium Regulation in the Cardiac Cell;Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways;Signaling by GPCR;Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding;Signaling by WNT;Signal Transduction;Glucagon signaling in metabolic regulation;GPCR Dopamine D1like receptor;GPCR Adenosine A2A receptor;Thromboxane signalling through TP receptor;GPCR GroupI metabotropic glutamate receptor;Metabolism of proteins;GPCR signaling-G alpha q;ADP signalling through P2Y purinoceptor 12;GPCR signaling-cholera toxin;GPCR signaling-pertussis toxin;Chaperonin-mediated protein folding;Metabolism;G alpha (s) signalling events;Presynaptic function of Kainate receptors;Activation of kainate receptors upon glutamate binding;Adrenaline,noradrenaline inhibits insulin secretion;Transport of small molecules;Glucagon-like Peptide-1 (GLP1) regulates insulin secretion;Regulation of insulin secretion;Signal amplification;Neuronal System;CRH;Thrombin signalling through proteinase activated receptors (PARs);Glucagon-type ligand receptors;Class B/2 (Secretin family receptors);GPCR ligand binding;GPCR signaling-G alpha s Epac and ERK;Platelet activation, signaling and aggregation;GPCR signaling-G alpha s PKA and ERK;Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits;Activation of GABAB receptors;Ca2+ pathway;Beta-catenin independent WNT signaling;ADP signalling through P2Y purinoceptor 1;Hemostasis;Protein folding;G-protein activation;GABA B receptor activation;GABA receptor activation;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;Opioid Signalling;G alpha (i) signalling events;G alpha (12/13) signalling events;G alpha (z) signalling events;GPCR signaling-G alpha i;Vasopressin regulates renal water homeostasis via Aquaporins;Aquaporin-mediated transport;Activation of G protein gated Potassium channels;G beta:gamma signalling through PLC beta;Prostacyclin signalling through prostacyclin receptor;Integration of energy metabolism;Platelet homeostasis;G alpha (q) signalling events;G beta:gamma signalling through PI3Kgamma;G-protein beta:gamma signalling;GPCR downstream signalling;G protein gated Potassium channels;Inwardly rectifying K+ channels;Potassium Channels;Visual signal transduction: Cones
(Consensus)
Recessive Scores
- pRec
- 0.281
Intolerance Scores
- loftool
- 0.710
- rvis_EVS
- -0.4
- rvis_percentile_EVS
- 26.73
Haploinsufficiency Scores
- pHI
- 0.151
- hipred
- N
- hipred_score
- 0.412
- ghis
- 0.552
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.517
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gnb3
- Phenotype
- vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- protein folding;cell volume homeostasis;G protein-coupled receptor signaling pathway;regulation of blood pressure;regulation of gene expression;regulation of glucose metabolic process;regulation of hormone metabolic process;regulation of fat cell differentiation;regulation of feeding behavior;regulation of cholesterol metabolic process;regulation of triglyceride metabolic process;regulation of locomotion involved in locomotory behavior;regulation of phospholipid metabolic process
- Cellular component
- cytosol;plasma membrane;dendrite;cell body;extracellular exosome
- Molecular function
- GTPase activity;protein binding;spectrin binding;GTPase binding